Should The Gleason Grading System For Prostate Cancer Be Modified To Account For High-Grade Tertiary Components? A Systematic Review And Meta-Analysis
Main Category: Prostate / Prostate CancerAlso Included In: Urology / Nephrology; Men's health; Medical Devices / Diagnostics
Article Date: 21 May 2007 - 0:00 PDT
| Patient / Public: | ![]() |
5 (1 votes) |
| Healthcare Prof: | ![]() |
5 (1 votes) |
UroToday.com- A systematic review and meta-analysis by Dr. Harnden and associates suggests that a tertiary Gleason grade is associated with worse oncologic prostate cancer (CaP) outcomes and warrants greater prospective analysis and consideration for inclusion in the Gleason grading system. This report appears in the May 2007 issue of the Lancet Oncology.
The standard prostate pathology report includes a primary and secondary Gleason grade. On some occasions, a tertiary grade is reported. In 2005 an International Consensus Conference of uro-pathologists suggested that the Gleason system for prostatic biopsy reports should be modified to account for the presence of a poorly differentiated or undifferentiated tertiary component. The modified approach would sum the most prevalent primary grade and the highest grade. Thus, in the situation with a primary grade 3 and a secondary grade 4, cancers with a tertiary grade of 5 would be classified as high grade (3+5). This proposal has not been implemented, as the existing system is well rooted in clinical practice.
A systematic review of the literature was performed to identify all studies that assessed the prognostic value of a tertiary Gleason pattern. The risk ratio was calculated for PSA recurrence in the presence of a tertiary pattern. In one study of 101 completely sectioned whole-mount radical prostatectomy specimens, the number of different grades was 2.7. In total, 7 papers addressed this topic. Two studies reported on the prognostic significance of a high-grade tertiary component and pathological outcome.
The presence of a tertiary Gleason grade was more common in patients with extraprostatic extension (77%) compare to organ-confined disease (32%). For Gleason 5-6, a high-grade tertiary component was more commonly seen in patients with focal or extensive extraprostatic extension than in those with organ-confined disease. This was significant for extensive, but not focal tumor extension.
There was a significantly higher frequency of a tertiary grade in the presence of seminal vesicle invasion for all Gleason scores combined, compared with that when SV invasion was not present. A difference was not discernable regarding lymph node involvement. Studies demonstrated that a tertiary grade was more than twice as likely to be associated with a positive rather than a negative margin (57% vs. 27%). Also, cancers with a Gleason score of 3+4 had a significantly higher frequency of positive surgical margins when a tertiary grade was present than when no tertiary grade was present (28% vs. 8%). Patients with a Gleason score of 4+3 had twice the frequency of positive surgical margins if a tertiary component was present than if absent (28% vs. 8%). Patients with a Gleason score of 7 and a tertiary grade 5 had similar outcomes to those with a score of 8. However, equivalence was not found between patients with Gleason score 4+3 and tertiary grade 5 and those with Gleason 4+5, as the latter group is more likely to have SV invasion or lymph node metastasis.
Harnden P, Shelley MD, Coles B, Staffurth J, Mason MD
Lancet Oncology 2007; 8(5):411-419
Reviewed by UroToday.com Contributing Editor Christopher P. Evans, MD
UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.
To access the latest urology news releases from UroToday, go to: www.urotoday.com
Copyright © 2006 - UroToday
Visit our prostate / prostate cancer section for the latest news on this subject.
MLA
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/71565.php>
APA
http://www.medicalnewstoday.com/releases/71565.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



